Abstract
seen a flurry of biotech deals: On Aug. 4, Gilead Sciences disclosed that it would acquire MiroBio for $405 million, and Amgen announced plans to nab ChemoCentryx for $3.7 billion. On Aug. 8, Pfizer said it would pay $5.4 billion in cash for Global Blood Therapeutics; the next day, CSL completed its purchase of Vifor Pharma for $11.7 billion, the largest deal announced in the industry last year. UK-based MiroBio specializes in developing a class of antibodies called immune inhibitory receptor agonists to treat autoimmune diseases. The molecules “agonize” overactive immune cells by binding to their receptors to quiet them. “We’re targeting very specific immune cell receptors,” says Eliot Charles, MiroBio’s chair . “The hope is that this is going to translate to safer medicines, because we’re not just dampening down the whole immune system but going after very specific pathways.” MiroBio’s lead investigational antibody is in Phase 1 clinical
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
